Loading...

PODCAST

The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week"s biggest moves in pharma and biotech. Covering drug approvals, licensing and M&A deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for pharma and biotech professionals who need to stay ahead. Transcripts,

science life sciences

All Episodes

00:10:20

Roche Divarasib Beats Both KRAS G12C Rivals in Phase...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/04

Roche's divarasib beats both KRAS G12C rivals on PFS and OS in head-to-head Phase 3, hitting survival significance at interim. AstraZeneca returns to CSPC in a $1.7B siRNA kidney disease deal; Abivax surges on $920M raise and cleared obefazimod cancer concerns; Ipsen acquires Memo Therapeutics; BridgeBio secures $1B; Scribe Therapeutics files for IPO; FDA CBER gene therapy leadership transition.Visit us at www.thepharmacloseout.comRoche's divarasib beats both KRAS G12C rivals on PFS and OS in

en-us

00:10:04

July 01, 2026| Tregzi Approved — Orca Bio Opens a New...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/02

FDA approves Orca Bio's Tregzi — the first precision-engineered cell therapy for allogeneic transplant, sparking IPO speculation. Plus BridgeBio secures $1B from Sixth Street and KKR at a 100%+ conversion premium, Ipsen's $2.55B deal spree continues with Memo Therapeutics,Merck scraps Alzheimer's drug MK-1167 as AlzeCure lands a $2.2B QuantumCell partnership, and FDA warns Sanofi's Genzyme over Altuviiio production. Visit us at www.thepharmacloseout.compharma, biotech, FDA, clinical

en-us

00:10:53

Jun 30, 2026 | NEJM Retracts Tavneos Pivotal Trial;...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/07/01

NEJM retracts Amgen's ADVOCATE study after FDA findsendpoint data for 9 patients re-evaluated post-unblinding. Plus: Ionis faces the Tryngolza sNDA PDUFA in severe hypertriglyceridemia, AbbVie's Epkinly delivers chemo-free PFS in R/R DLBCL, Ipsen acquires Kartos for up to $1.75B,and Roche enters the TED race with Enspryng Priority Review.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout,

en-us

00:14:12

Jun 26, 2026 | FDA Approves Viridian for Thyroid Eye...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/06/27

FDA breaks Amgen's Tepezza monopoly with Viridian's Lumvoa approval in thyroid eye disease. Plus Merck KGaA's $11.3B Bio-Techne acquisition, Biogen gutting the Apellis pipeline post-$5.6B deal, CHMP moves to revoke Tavneos, and Lilly's orforglipron PDUFA lands Monday.Www.thepharacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Viridian Therapeutics, Lumvoa, veligrotug, thyroid eye disease, Amgen, Tepezza, Merck KGaA,

en-us

00:09:53

Jun 25, 2026 | Ionis Tryngolza FDA Label Expansion...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/06/26

FDA approves Ionis Tryngolza as first treatment to reduce pancreatitis risk in severe hypertriglyceridemia — a potential blockbuster expansion. Merck KGaA acquires Bio-Techne for $11.3B in largest deal in a decade. SCOTUS limits Bayer Roundup state-level claims; Gilead-Pfizer ADC divergence deepens.pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Ionis, Tryngolza, olezarsen, hypertriglyceridemia, pancreatitis, FDA approval, Merck

en-us

00:13:02

Jun 24, 2026 | FDA Approves Gilead's Trodelvy for...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/06/25

Gilead's Trodelvy wins front-line triple-negative breast cancer approval — and the stock barely moves. Lilly expands its Abbisko partnership to $1.9B, Novartis pays $105M upfront to Antares for undruggable cancer targets, and three ADC stories in two days force a class-level reckoning.pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Trodelvy, sacituzumab govitecan, Gilead, TNBC, triple-negative breast cancer, FDA approval, Eli

en-us

00:14:00

Jun 23, 2026 | Pfizer Seagen ADC Fails in Lung Cancer...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/06/24

Pfizer's sigvotatug vedotin disappoints in Phase 3 NSCLC — another blow to the $43B Seagen deal. Plus CMS settles with Incyte on Opzelura classification, Sangamo Therapeutics closes after 30 years, and Moderna's flu vaccine wins unanimous FDA panel support.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Pfizer, Seagen, sigvotatug vedotin, ADC, antibody-drug conjugate, non-small cell lung

en-us

00:10:01

Jun 22, 2026 | AbbVie's $10.9B Apogee Buy Targets...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/06/23

AbbVie bets $10.9B on Apogee Therapeutics to challenge Dupixent — its biggest deal since Allergan. Plus: the first CAR-T approved for a solid tumor clears in China, Merck's $10.8B Prometheus IBD bet pays off with a Phase 3 win, and HHS clinical trial reforms target China. Visit www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, AbbVie, Apogee Therapeutics, zumilokibart, Dupixent, Regeneron, Sanofi, CARsgen,

en-us

00:10:48

Jun 19, 2026 | US Probes Germany Drug Pricing;...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/06/20

US government opens formal probe into Germany's drug pricing reforms, escalating transatlantic pharma trade tensions. Kardigan IPO raises $400M and pops 31%. Moderna flu vaccine gets unanimous FDA advisory panel support ahead of Aug 5 PDUFA. Jazz and AbCellera strike $4.1B T cell engager collaboration.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Germany drug pricing, US trade probe,

en-us

00:13:30

Jun 18, 2026 | Moderna mFlusiva Wins Unanimous VRBPAC...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/06/19

Moderna's mRNA flu vaccine gets unanimous FDA panel backing — PDUFA August 5. NovoCure's TRIDENT trial misses overall survival in glioblastoma; stock drops ~18%. Biogen acquires immunology startup RayThera for up to $1B; Kardigan IPO raises $400M.Visit us at www.thepharmacloseput.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Moderna, mFlusiva, MRNA, VRBPAC, mRNA flu vaccine, NovoCure, NVCR, TRIDENT, glioblastoma, TTFields,

en-us

00:14:18

Jun 17, 2026 | UniQure AMT-130 Surges 70% on FDA...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/06/18

UniQure surges 70% as FDA reverses course on Huntington's gene therapy AMT-130 filing path. Jazz and AbCellera strike $4.1B T cell engager deal for GI cancers. Novo Nordisk faces $25M ransom demand after hackers claim drug formulations and AI models. Visit www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, UniQure, QURE, AMT-130, Huntington's disease, gene therapy, FDA accelerated approval, Jazz

en-us

00:10:35

Jun 16, 2026 | BridgeBio BBP-418 Sweeps LGMD Phase 3;...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/06/17

BridgeBio's BBP-418 sweeps Phase 3 in limb-girdle muscular dystrophy — stock up 15%, no approved competition. FDA briefing docs challenge Moderna mFlusiva efficacy ahead of Thursday's VRBPAC vote. Plus Lilly acquires non-opioid pain startup 4E Therapeutics, Edgewise advances EDG-7500 toward Phase 3 in HCM, and Neumora abandons navacaprant after two Phase 3 failures.Visit www.thepharmacloseput.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The

en-us

00:10:21

Jun 15, 2026 | CMS Targets SubQ Keytruda and Opdivo...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/06/16

CMS proposes closing Medicare negotiation loophole threatening Keytruda and Opdivo subcutaneous strategies — billions at stake. Plus Takeda's zasocitinib tops Sotyktu, Novartis validates $12B Avidity deal, Elicio's KRAS vaccine crashes, and FDA approves Truqap in prostate cancer and Tzield for pediatric T1D.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, CMS, Medicare drug price negotiation,

en-us

00:20:12

EHA 2026 Special — Full Meeting Recap

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/06/15

The Pharma Closeout's comprehensive recap of EHA 2026(Stockholm, June 11-14). HEADLINE: J&J's MonumenTAL-3 (talquetamab +daratumumab) in earlier-line R/R myeloma — PFS HR 0.28/0.33, complete-response 71% vs 34.5%, NEJM-published; ~73% dysgeusia the caveat.AML: the menin inhibitor frontline class war — ziftomenib KOMET-007 (CRc 96% NPM1m / 90%KMT2Ar) vs revumenib (frontline CRc 97%; SAVE ORR 88%) — and the gilteritinib-vs-midostaurin FLT3 survival miss (HR 1.02). CLL: BRUIN CLL-322 —

en-us

00:13:46

Jun 12, 2026 | FDA Approves Merck Welireg-Keytruda...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/06/13

FDA approves Merck's Welireg-Keytruda combo for adjuvant kidney cancer — 28% risk reduction vs. active Keytruda monotherapy in LITESPARK-022. Jazz's Zepzelca misses OS endpoint in Phase 3 LAGOON, Incyte acquires Vega Therapeutics for $1.25B, and Amgen files independent Duke review to fight FDA's proposed Tavneos withdrawal.pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Merck, Keytruda, Welireg, belzutifan, pembrolizumab, kidney

en-us

00:10:01

Jun 11, 2026 | Takeda Zasocitinib Beats Sotyktu in...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/06/12

Zasocitinib hits 35% complete skin clearance at week 16,topping Sotyktu by more than 2.5x in Takeda's head-to-head Phase 3. Plus: Novartis validates its $12B Avidity AOC platform in FSHD, Summit withdraws $500M offering, and Genentech reshapes its research organization.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, zasocitinib, Takeda, Sotyktu, deucravacitinib, Bristol Myers Squibb, TYK2,

en-us

00:25:56

ADA 2026 Special: The full recap

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/06/11

The Pharma Closeout's full recap of the American Diabetes Association's 86th Scientific Sessions (New Orleans,June 5-8, 2026) - the meeting that ended the A1C-only era and reset what obesity medicine can do. Hosts Alex Mercer and Maya Patel walk every major readout, with the commercial read on each.Visit us at www.thepharmacloseout.comADA 2026, American DiabetesAssociation, diabetes, obesity, GLP-1, retatrutide, orforglipron, tirzepatide, semaglutide, CagriSema, survodutide, MASH, type 1

en-us

00:09:44

un 10, 2026 | Parabilis Sets Record $670M Biotech...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/06/11

Parabilis Medicines prices the largest-ever venture-backed biotech IPO at $670M as 12 startups top $4.1B in 2026. Sanofi stops MOBILIZE Phase 3 for riliprubart in CIDP. TG Therapeutics surges on Briumvi myasthenia gravis data. AstraZeneca's oral GLP-1 elecoglipron hits 11.8% weight loss.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Parabilis Medicines, biotech IPO, zolucatetide, TG

en-us

00:18:06

The AI Vendor Draft — How Big Pharma Picked Its AI...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/06/08

In about six weeks this spring, four of the biggest names in pharma each picked an AI partner — Bristol Myers Squibb chose Anthropic's Claude for 30,000+ employees, Merck signed with Google Cloud for up to $1B, Novo Nordisk went with OpenAI, and Eli Lilly built what NVIDIA calls the industry's most powerful AI supercomputer. A Pharma Closeout Special Report, fact-checked against the primary company and FDA releases, on what they actually bought — and who's likely to be proven right.Visit

en-us

00:11:21

Jun 07, 2026 | Alnylam's $2B AI-RNA Deal with...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/06/08

Alnylam commits up to $2B to Inceptive Nucleics forAI-driven RNAi drug discovery — $30M upfront, milestone-heavy structure. Lundbeck's bocunebart hits Phase IIb primary endpoint with 1.38-day treatmentdifference in refractory migraine. Plus Otsuka Voyxact IgAN data, Replimune's third RP1 submission, the Supreme Court's skinny label ruling, and Biogen's salanersen Breakthrough Therapy Designation.

en-us

172 results

Similar Podcasts

Science Weekly

The Guardian

La Science CQFD

France Culture

The Dirt: an eKonomics podKast

eKonomics

La Science, CQFD

France Culture

Travelers In The Night

Albert D. Grauer